About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Global Digital Biomarkers Market Size, Top Share, Demand, Report to 2032
Digital Biomarkers Market

Digital Biomarkers Market Size, Share & Trends Analysis Report By Type (Data Collection Tools, Data Integration Tools), By Clinical Practice (Diagnostic, Monitoring, Prognostic, Predictive, Others), By Therapeutic Area (Cardiovascular and Metabolic Disorders, Respiratory Disorders, Neurological Disorders, Musculoskeletal Disorders, Psychiatric Disorders, Other Applications), By End-User (Pharmaceutical Companies, Healthcare Providers, Payers, Other End-Users) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRHI2125DR
Last Updated : November 18, 2024
Author : Debashree Bora
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Digital Biomarkers Market Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Data Collection Tools
        1. By Value
      3. Data Integration Tools
        1. By Value
    3. By Clinical Practice
      1. Introduction
        1. Clinical Practice By Value
      2. Diagnostic
        1. By Value
      3. Monitoring
        1. By Value
      4. Prognostic
        1. By Value
      5. Predictive
        1. By Value
      6. Others
        1. By Value
    4. By Therapeutic Area
      1. Introduction
        1. Therapeutic Area By Value
      2. Cardiovascular and Metabolic Disorders
        1. By Value
      3. Respiratory Disorders
        1. By Value
      4. Neurological Disorders
        1. By Value
      5. Musculoskeletal Disorders
        1. By Value
      6. Psychiatric Disorders
        1. By Value
      7. Other Applications
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical Companies
        1. By Value
      3. Healthcare Providers
        1. By Value
      4. Payers
        1. By Value
      5. Other End-Users
        1. By Value
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Data Collection Tools
        1. By Value
      3. Data Integration Tools
        1. By Value
    3. By Clinical Practice
      1. Introduction
        1. Clinical Practice By Value
      2. Diagnostic
        1. By Value
      3. Monitoring
        1. By Value
      4. Prognostic
        1. By Value
      5. Predictive
        1. By Value
      6. Others
        1. By Value
    4. By Therapeutic Area
      1. Introduction
        1. Therapeutic Area By Value
      2. Cardiovascular and Metabolic Disorders
        1. By Value
      3. Respiratory Disorders
        1. By Value
      4. Neurological Disorders
        1. By Value
      5. Musculoskeletal Disorders
        1. By Value
      6. Psychiatric Disorders
        1. By Value
      7. Other Applications
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical Companies
        1. By Value
      3. Healthcare Providers
        1. By Value
      4. Payers
        1. By Value
      5. Other End-Users
        1. By Value
    6. U.S.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Data Collection Tools
          1. By Value
        3. Data Integration Tools
          1. By Value
      2. By Clinical Practice
        1. Introduction
          1. Clinical Practice By Value
        2. Diagnostic
          1. By Value
        3. Monitoring
          1. By Value
        4. Prognostic
          1. By Value
        5. Predictive
          1. By Value
        6. Others
          1. By Value
      3. By Therapeutic Area
        1. Introduction
          1. Therapeutic Area By Value
        2. Cardiovascular and Metabolic Disorders
          1. By Value
        3. Respiratory Disorders
          1. By Value
        4. Neurological Disorders
          1. By Value
        5. Musculoskeletal Disorders
          1. By Value
        6. Psychiatric Disorders
          1. By Value
        7. Other Applications
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical Companies
          1. By Value
        3. Healthcare Providers
          1. By Value
        4. Payers
          1. By Value
        5. Other End-Users
          1. By Value
    7. Canada
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Data Collection Tools
        1. By Value
      3. Data Integration Tools
        1. By Value
    3. By Clinical Practice
      1. Introduction
        1. Clinical Practice By Value
      2. Diagnostic
        1. By Value
      3. Monitoring
        1. By Value
      4. Prognostic
        1. By Value
      5. Predictive
        1. By Value
      6. Others
        1. By Value
    4. By Therapeutic Area
      1. Introduction
        1. Therapeutic Area By Value
      2. Cardiovascular and Metabolic Disorders
        1. By Value
      3. Respiratory Disorders
        1. By Value
      4. Neurological Disorders
        1. By Value
      5. Musculoskeletal Disorders
        1. By Value
      6. Psychiatric Disorders
        1. By Value
      7. Other Applications
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical Companies
        1. By Value
      3. Healthcare Providers
        1. By Value
      4. Payers
        1. By Value
      5. Other End-Users
        1. By Value
    6. U.K.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Data Collection Tools
          1. By Value
        3. Data Integration Tools
          1. By Value
      2. By Clinical Practice
        1. Introduction
          1. Clinical Practice By Value
        2. Diagnostic
          1. By Value
        3. Monitoring
          1. By Value
        4. Prognostic
          1. By Value
        5. Predictive
          1. By Value
        6. Others
          1. By Value
      3. By Therapeutic Area
        1. Introduction
          1. Therapeutic Area By Value
        2. Cardiovascular and Metabolic Disorders
          1. By Value
        3. Respiratory Disorders
          1. By Value
        4. Neurological Disorders
          1. By Value
        5. Musculoskeletal Disorders
          1. By Value
        6. Psychiatric Disorders
          1. By Value
        7. Other Applications
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical Companies
          1. By Value
        3. Healthcare Providers
          1. By Value
        4. Payers
          1. By Value
        5. Other End-Users
          1. By Value
    7. Germany
    8. France
    9. Spain
    10. Italy
    11. Russia
    12. Nordic
    13. Benelux
    14. Rest of Europe
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Data Collection Tools
        1. By Value
      3. Data Integration Tools
        1. By Value
    3. By Clinical Practice
      1. Introduction
        1. Clinical Practice By Value
      2. Diagnostic
        1. By Value
      3. Monitoring
        1. By Value
      4. Prognostic
        1. By Value
      5. Predictive
        1. By Value
      6. Others
        1. By Value
    4. By Therapeutic Area
      1. Introduction
        1. Therapeutic Area By Value
      2. Cardiovascular and Metabolic Disorders
        1. By Value
      3. Respiratory Disorders
        1. By Value
      4. Neurological Disorders
        1. By Value
      5. Musculoskeletal Disorders
        1. By Value
      6. Psychiatric Disorders
        1. By Value
      7. Other Applications
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical Companies
        1. By Value
      3. Healthcare Providers
        1. By Value
      4. Payers
        1. By Value
      5. Other End-Users
        1. By Value
    6. China
      1. By Type
        1. Introduction
          1. Type By Value
        2. Data Collection Tools
          1. By Value
        3. Data Integration Tools
          1. By Value
      2. By Clinical Practice
        1. Introduction
          1. Clinical Practice By Value
        2. Diagnostic
          1. By Value
        3. Monitoring
          1. By Value
        4. Prognostic
          1. By Value
        5. Predictive
          1. By Value
        6. Others
          1. By Value
      3. By Therapeutic Area
        1. Introduction
          1. Therapeutic Area By Value
        2. Cardiovascular and Metabolic Disorders
          1. By Value
        3. Respiratory Disorders
          1. By Value
        4. Neurological Disorders
          1. By Value
        5. Musculoskeletal Disorders
          1. By Value
        6. Psychiatric Disorders
          1. By Value
        7. Other Applications
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical Companies
          1. By Value
        3. Healthcare Providers
          1. By Value
        4. Payers
          1. By Value
        5. Other End-Users
          1. By Value
    7. Korea
    8. Japan
    9. India
    10. Australia
    11. Singapore
    12. Taiwan
    13. South East Asia
    14. Rest of Asia-Pacific
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Data Collection Tools
        1. By Value
      3. Data Integration Tools
        1. By Value
    3. By Clinical Practice
      1. Introduction
        1. Clinical Practice By Value
      2. Diagnostic
        1. By Value
      3. Monitoring
        1. By Value
      4. Prognostic
        1. By Value
      5. Predictive
        1. By Value
      6. Others
        1. By Value
    4. By Therapeutic Area
      1. Introduction
        1. Therapeutic Area By Value
      2. Cardiovascular and Metabolic Disorders
        1. By Value
      3. Respiratory Disorders
        1. By Value
      4. Neurological Disorders
        1. By Value
      5. Musculoskeletal Disorders
        1. By Value
      6. Psychiatric Disorders
        1. By Value
      7. Other Applications
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical Companies
        1. By Value
      3. Healthcare Providers
        1. By Value
      4. Payers
        1. By Value
      5. Other End-Users
        1. By Value
    6. UAE
      1. By Type
        1. Introduction
          1. Type By Value
        2. Data Collection Tools
          1. By Value
        3. Data Integration Tools
          1. By Value
      2. By Clinical Practice
        1. Introduction
          1. Clinical Practice By Value
        2. Diagnostic
          1. By Value
        3. Monitoring
          1. By Value
        4. Prognostic
          1. By Value
        5. Predictive
          1. By Value
        6. Others
          1. By Value
      3. By Therapeutic Area
        1. Introduction
          1. Therapeutic Area By Value
        2. Cardiovascular and Metabolic Disorders
          1. By Value
        3. Respiratory Disorders
          1. By Value
        4. Neurological Disorders
          1. By Value
        5. Musculoskeletal Disorders
          1. By Value
        6. Psychiatric Disorders
          1. By Value
        7. Other Applications
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical Companies
          1. By Value
        3. Healthcare Providers
          1. By Value
        4. Payers
          1. By Value
        5. Other End-Users
          1. By Value
    7. Turkey
    8. Saudi Arabia
    9. South Africa
    10. Egypt
    11. Nigeria
    12. Rest of MEA
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Data Collection Tools
        1. By Value
      3. Data Integration Tools
        1. By Value
    3. By Clinical Practice
      1. Introduction
        1. Clinical Practice By Value
      2. Diagnostic
        1. By Value
      3. Monitoring
        1. By Value
      4. Prognostic
        1. By Value
      5. Predictive
        1. By Value
      6. Others
        1. By Value
    4. By Therapeutic Area
      1. Introduction
        1. Therapeutic Area By Value
      2. Cardiovascular and Metabolic Disorders
        1. By Value
      3. Respiratory Disorders
        1. By Value
      4. Neurological Disorders
        1. By Value
      5. Musculoskeletal Disorders
        1. By Value
      6. Psychiatric Disorders
        1. By Value
      7. Other Applications
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical Companies
        1. By Value
      3. Healthcare Providers
        1. By Value
      4. Payers
        1. By Value
      5. Other End-Users
        1. By Value
    6. Brazil
      1. By Type
        1. Introduction
          1. Type By Value
        2. Data Collection Tools
          1. By Value
        3. Data Integration Tools
          1. By Value
      2. By Clinical Practice
        1. Introduction
          1. Clinical Practice By Value
        2. Diagnostic
          1. By Value
        3. Monitoring
          1. By Value
        4. Prognostic
          1. By Value
        5. Predictive
          1. By Value
        6. Others
          1. By Value
      3. By Therapeutic Area
        1. Introduction
          1. Therapeutic Area By Value
        2. Cardiovascular and Metabolic Disorders
          1. By Value
        3. Respiratory Disorders
          1. By Value
        4. Neurological Disorders
          1. By Value
        5. Musculoskeletal Disorders
          1. By Value
        6. Psychiatric Disorders
          1. By Value
        7. Other Applications
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical Companies
          1. By Value
        3. Healthcare Providers
          1. By Value
        4. Payers
          1. By Value
        5. Other End-Users
          1. By Value
    7. Mexico
    8. Argentina
    9. Chile
    10. Colombia
    11. Rest of LATAM
    1. Digital Biomarkers Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Alphabet Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. AliveCor Inc.
    3. Akili Interactive Labs, Inc.
    4. Cambridge Cognition Ltd
    5. Dassault Systèmes
    6. IXICO plc
    7. Koninklijke Philips N.V
    8. Shimmer
    9. Quanterix Corporation
    10. Altoida AG
    11. Happify, Inc.
    12. Huma
    13. Human API
    14. Mindstrong Health
    15. Neurotrack Technologies, Inc
    16. Orikami
    17. Winterlight Labs Inc.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global biomarkers market size was valued at USD 58,448 million in 2021, presumed to reach USD 169,676 million, expanding at a CAGR of 14.25% during the forecast period.  The utilization of biomarkers in basic and clinical research and clini
Buy Now
Global Report
The global cardiac biomarkers market size was valued at USD 14.73 billion in 2022. It is estimated to reach USD 48.66 billion by 2031, growing at a CAGR of 14.2% during the forecast period (2023–2031). Cardiac biomarkers are substances th
Buy Now
Global Report
Digital Ink Market Size The global digital ink market accounted for a market value of USD 6.4 billion in 2024 and is estimated to reach an expected value USD 6.8 billion by 2025 to USD 11.2 billion by 2033 at a CAGR of 6.4% during the
Buy Now
Global Report
Digital Map Market Size The global digital map market size was valued at USD 24.21 billion in 2024 and is projected to reach from USD 27.24 billion in 2025 to USD 69.89 billion by 2033, growing at a CAGR of 12.5% during the forecast period (2025-203
Buy Now
Global Report
The global digital signature market size was valued at USD 7.13 billion in 2023. It is expected to reach USD 62.28 billion in 2032, growing at a CAGR of 27.23% over the forecast period (2024-2032). Government regulations and legal frameworks increasi
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.